Overview
Stock Info
Quarterlies
| Date | Form | Description | Download |
|---|---|---|---|
| Nov 12, 2024 | 10-Q | Quarterly Report - 2024 Q3 |      |
| Aug 12, 2024 | 10-Q | Quarterly Report - 2024 Q2 | |
| May 13, 2024 | 10-Q | Quarterly Report - 2024 Q1 | |
Events
Add to CalendarSession Title: Transcriptional, Epigenetic and Genetic Regulation of GI Function and Disease
Session Date & Time: May 4, 12:30 PM to 1:30 PM PDT
Title: A BIOINFORMATIC APPROACH TO PALI-2108 TREATMENT IN ULCERATIVE COLITIS REVEALS THE POTENTIAL FOR ANTI-FIBROTIC EFFICACY WITH LOCAL PDE4 INHIBITION IN INTESTINAL FIBROSIS
DDW Poster of Distinction – Poster Presentation
Session Title: In Vivo Models of Gastrointestinal Disorders
Session Date & Time: May 5, 12:30 PM to 1:30 PM PDT
Title: PALI-2108, A COLON-SPECIFIC PDE4 INHIBITOR PRODRUG, IS BIOACTIVATED IN THE COLON AND REDUCES COLON TISSUE PDE4B IN A DOSE-DEPENDENT MANNER, INCREASING C-AMP AND SUPPRESSING TNF- IN A MOUSE MODEL OF COLI
Stay Updated
Corporate Presentation
Analyst Coverage
Palisade Bio is followed by the analysts listed here. Please note that any opinions, estimates or forecasts regarding Palisade Bio’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Palisade Bio or its management. Palisade Bio does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Company
Palisade Bio is a clinical stage biopharmaceutical company dedicated to advancing next-generation precision therapies for immune, inflammatory, and fibrotic diseases. These conditions represent a significant unmet need, leading to chronic organ dysfunction, damage and even failure due to abnormal immune responses and persistent inflammation.
Our lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis represents a significant challenge for patients, who are in need of therapies that provide effective remission rates, are non-immunosuppressive and have improved safety.